The results of Prana's Phase 2 trial in Huntington’s disease, Reach2HD, has been published in The Lancet Neurology, one of the world’s leading medical journals.
A new report studying Alzheimer's disease and co-authored by Professor Rudy Tanzi has been published by the respected journal Nature.
The Prana Biotechnology 2014 Annual Report summarises the Company's achievements over the past 12 months
Prana Biotechnology (ASX:PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.
Prana Biotechnology (ASX:PBT) has today provided an update on its clinical development program for Alzheimer’s disease.
Professor Ira Shoulson comments on joining Prana Biotechnology's Board of Directors.
Professor Ira Shoulson will join Prana Biotechnology's Board of Directors as a non-Executive Director.
MELBOURNE, March 31, 2014: Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer’s Disease (“IMAGINE” Trial), based on draft results. Prana’s PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well.
MARCH 2014: Accumulation and toxicity of Alzheimer’s-related beta-amyloid independently confirmed to be dependent on copper and arrested with Prana’s proof-of-concept MPAC.